Skip to main content

HFpEF and diabetes

Diagnosis and management in the wake of EMPEROR-Preserved

Watch on-demand

Join cardiologist Lars Rydén, endocrinologist Alice Cheng, and primary care practitioner Kevin Saunders who discuss the diagnosis and management of people with type 2 diabetes and shortness of breath in primary care, and how the positive findings of EMPEROR-Preserved will now shape the care of these patients. Watch now

Keep up with the latest news on HFpEF

02-09-2022 | Dapagliflozin | News

DELIVER results round-up: Frailty, AF, recent hospitalization, and more

A flurry of publications accompanying the primary findings of DELIVER shows dapagliflozin to benefit a wide range of people who have heart failure with preserved ejection fraction.

31-08-2022 | Heart failure | News

‘Strikingly consistent’ evidence for SGLT2 inhibitor benefits across the spectrum of heart failure

SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.

27-08-2022 | Dapagliflozin | News

Dapagliflozin DELIVERs improved HFpEF outcomes

Dapagliflozin significantly reduces the risk for worsening heart failure or cardiovascular death in people who have heart failure with preserved ejection fraction, show the results of the DELIVER trial.

27-08-2021 | ESC 2021 | Conference coverage | News

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Interviews on heart failure

Mikhail Kosiborod

01-11-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

Kevin Fernando

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: The implications for primary care

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

Stefan Anker

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.

Adriaan Voors

02-03-2022 | Empagliflozin | Video

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox